AustriaAustria

Partial PID approval rejected

28.09.2005


Vienna - The disputed pre-implantation diagnosis (PID) will not be introduced in Austria for the time being. In mid-September the Austrian conservative health minister Maria Rauch-Kallat (ÖVP) withdrew a passage in the draft of the genetic engineering law, which is currently debated in the Council of Ministers. The new law would have permitted PID of artificially fertilized embryos, which is forbidden so far in a number of specific cases. Against the partial approval were the Association for Life (Aktion Leben) and the Ministry of Justice, which had expressed doubts. The catholic church welcomed the decision. The ministerial draft had envisaged to permit PID only after at least three failed attempts of an artificial fertilization had raised suspicions that the implanted fetus would die due to a genetic defect before or soon after birth. In these cases - and not with serious disabilities like the down syndrome - fertilized ovums in which the defect did not exist should have been selected.

Politics / Law, AustriaAustria

14.07.2009

The cultivation of genetically modified organisms (GMOs) in the European Union could soon no longer be decided by scientific facts, but by political preferences. Fourteen member states – among them France, Poland and Portugal –...

AustriaAustria

04.06.2009

Vienna – Glycobiology specialist Prot­Affin AG has announced the completion of a EUR14.1m second round, co-led by Atlas Venture and SR One Ltd, the corporate venture fund of GlaxoSmithKline. Existing investors Aescap Venture,...

AustriaAustria

29.04.2009

Vienna – Intercell AG has received good news from the American Food and Drug Administration; its Japanese encephalitis vaccine Ixiaro® has now been approved in the US. That gives Intercell the chance to strike an important deal...

AustriaAustria

21.02.2009

Vienna/New York – Feeling safe activates cellular and molecular processes that act against depression (Neuron 60(1):149-61). A new animal model that helps examine and explain the relevant cell biology processes shows that...

AustriaAustria

21.02.2009

Vienna – Austria’s scientific community is worried about a cut in national research support due to the worldwide financial crisis. Last year, a105m were channeled to research in Austria through the “Jubiläumsfonds”, a foundation...

AustriaAustria

21.02.2009

Vienna – Austria’s scientific community is worried about a cut in national research support due to the worldwide financial crisis. Last year, a105m were channeled to research in Austria through the “Jubiläumsfonds”, a foundation...

AustriaAustria

20.02.2009

Austrian vaccine developer Intercell AG (Vienna) announced in January that it has initiated a Phase II clinical study to test IC43, a vaccine candidate to prevent opportunistic infections with Pseudomonas aeruginosa. The...

AustriaAustria

03.10.2008

Innsbruck – A heated debate on scientific misconduct in Austria has reached fresh heights after the Medical University of Innsbruck fired rector Clemens Sorg due to “severe breach of duty”. In a private letter to colleagues and...

AustriaAustria

14.08.2008

Graz – Austria-based metabolomics company Biocrates AG has entered into a worldwide co-marketing agreement with Applied Biosystems, the world leader in mass spectrometry to be overtaken by Invitrogen. Under the terms of the...

Displaying results 41 to 50 out of 116

< Previous 41-50 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-austria/browse/4/article/partial-pid-approval-rejected.html

Events

All Events

Stock list

All quotes

TOP

  • 4SC1.23 EUR6.03%
  • VITA 343.96 EUR4.49%
  • WILEX2.36 EUR4.42%

FLOP

  • CYTOS0.26 CHF-3.70%
  • MOLOGEN7.10 EUR-2.74%
  • ADDEX4.00 CHF-1.72%

TOP

  • SANTHERA82.95 CHF20.4%
  • LONZA101.10 CHF6.1%
  • MAGFORCE6.50 EUR5.7%

FLOP

  • WILEX2.36 EUR-25.1%
  • MOLOGEN7.10 EUR-24.5%
  • VITA 343.96 EUR-18.4%

TOP

  • SANTHERA82.95 CHF3758.1%
  • CO.DON2.50 EUR228.9%
  • PAION2.48 EUR195.2%

FLOP

  • CYTOS0.26 CHF-93.6%
  • MEDIGENE4.65 EUR-68.1%
  • MERCK KGAA64.40 EUR-45.7%

No liability assumed, Date: 22.08.2014


Current issue

All issues

Product of the week

Products